Gilead Drug Pipeline

Gilead Sciences maintains a substantial clinical portfolio, with 62 active trials out of 523 total trials registered since 2008. These active trials span multiple phases, including 16 in Phase 1, 28 in Phase 2, 26 in Phase 3, and 1 in Phase 4. The company's research and development efforts cover nine therapeutic areas, with a significant concentration in Oncology, which accounts for 52% of active programs. Within Oncology, key indications include Solid Tumor (Advanced), Triple Negative Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Breast Cancer, and Bladder Cancer. Infectious Disease represents the second-largest area of focus with 24 active trials, followed by Immunology with 4 active trials and Hepatology with 2. Notably, several Oncology programs are in Phase 3, particularly in Triple Negative Breast Cancer and NSCLC, suggesting a potential near-term focus on bringing these therapies to market. The portfolio indicates a strategic emphasis on Oncology, balanced with ongoing research in other key therapeutic areas.